A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Pre-digital era === During the pre-digital era, patients suffered from inefficient and faulty clinical systems, processes, and conditions. Many medical errors happened in the past due to undeveloped health technologies. Some examples of these medical errors included adverse drug events and alarm fatigue. When many alarms are repeatedly triggered or activated, especially for unimportant events, workers may become desensitized to the alarms. Healthcare professionals who have alarm fatigue may ignore an alarm believing it to be insignificant, which could lead to death and dangerous situations. With technological development, an intelligent program of integration and physiologic sense-making was developed and helped reduce the number of false alarms. Also, with greater investment in health technologies, fewer medical errors happened. Outdated paper records were replaced in many healthcare organizations by electronic health records (EHR), with adoption in the United States increasing rapidly from the late 2000s to near-universal use by the early 2020s. According to studies, this has brought many changes to healthcare. Drug administration has improved, healthcare providers can now access medical information easier, provide better treatments and faster results, and save more costs.
Opioid switching, also called opioid rotation, is the replacement of the current opioid with another pharmacological agent such as morphine or methadone. It was effective in some studies, but can increase sensitivity to pain, requiring higher doses of the opioid-sparing drug. Opioid rotation is a safe and effective alternative to completely stopping opioid therapy. Methadone is also believed to show some efficacy in OIH, presumably due to its weak NMDA antagonist activity. Ketamine, an NMDA antagonist, has been shown to prevent the extended use of opioid in post-operative hyperalgesia when it is infused in a small amount perioperatively along with the opioid but there are also studies that show ketamine being ineffective in modulating hyperalgesia. The use of an NSAID, especially some COX-2 inhibitors, or acetaminophen either as monotherapy or combination therapy is also suggested as a possible treatment option.
== History == In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis. In January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.
Sources: en.wikipedia.org
Historians Robert Friedel and Paul Israel list inventors of incandescent lamps prior to Joseph Swan and Thomas Edison of General Electric. They conclude that Edison's version was the first practical implementation, able to outstrip the others because of a combination of four factors: an effective incandescent material; a vacuum higher than other implementations; a high resistance that made power distribution from a centralized source economically viable, and the development of the associated components required for a large-scale lighting system. However, Joseph Swan's incandescent light bulb pre-dated Edison's and was sufficiently practical that it was actually installed and in daily use in London in 1881. Historian Thomas Hughes has attributed Edison's business success to his development of an entire, integrated system of electric lighting.
When journalists investigated this business connection, they also discovered that since the events of the protests in 2021, Urquía Carreño's construction company, SME Edificia, had on three separate occasions been subjected to intense and tedious investigations for alleged misconduct and malpractice by agents of the State Security Unit. It was also discovered that State Security agents told Urquía Carreño that if he complied with their wishes, they would leave his company alone. On February 22, 2024, only 48 hours after the first trial, the Supreme Court of Masonic Justice officially expelled Viñas Alonso from the Grand Lodge of Cuba and from the brotherhood of Freemasonry for a total of seven years. Viñas Alonso was given very short notice and could attend the trial, and Second Chamber President Brindisi Limonta was not informed of the proceedings. The Supreme Court's expulsion decision outcome document was not adorned with any signatures or any official seals. Brindisi Limonta expressed his displeasure that he was not invited to the oral hearing, and noted that this "oral hearing" did not even take place in the courthouse on the tenth floor of the National Masonic Temple, and most likely further violated the separation of powers because it was held in Urquía Carreño's office on the eleventh floor, the same office that was supposed to be under investigation by the police for the initial theft. Later that day, on February 22, Valdés García disbarred Brindisi Limonta as a magistrate of the Supreme Court of Masonic Justice.
Activated platelets have the ability to bind glycoproteins and glycolipids (P-selectin ligands such as PSGL-1) on the surface of cancer cells to form a physical barrier that protects the cancer cell from natural killer cell-mediated lysis in the bloodstream. Furthermore, activated platelets promote the adhesion of cancer cells to activated endothelial cells lining blood vessels using adhesion molecules present on platelets. P-selectin ligands on the surface of cancer cells remain to be elucidated and may serve as potential biomarkers for disease progression in cancer.
=== Early years === Brothers Jim and William Reid formed a band in the early 1980s in response to their distaste of the music at the time, saying, "It was the crap coming out of the radio that made us want to be in a band". This worked in their favour, as William said, "It was perfect timing because there weren't any guitar bands. Everybody was making this electronic pop music." Before forming the band, the brothers had spent five years on the dole, during which they wrote and recorded songs at home and worked out the sound and image of the band. Originally called The Poppy Seeds, and then Death of Joey, they initially told journalists that they had taken their eventual name from a line in a Bing Crosby film, although six months later they admitted that this was not true. Other accounts suggest that the name derived from an offer on a breakfast cereal packet, where customers could send off for a gold Jesus & Mary chain. As neither brother wanted to be the singer, they decided on Jim via coin toss. The brothers started recording and sending demos to record companies in 1983 (using a Portastudio bought with £300 given to them by their father from redundancy pay after he lost his factory job), and by early 1984 they had recruited bass player Douglas Hart and teenage drummer Murray Dalglish. Early influences included the Velvet Underground, the Stooges, New York Dolls, Suicide, the Shangri-Las, and Einstürzende Neubauten.
Sources: en.wikipedia.org
=== Origins === Modern dentistry in Chengdu developed in the early 20th century through the work of Western medical missionaries. Ashley Woodward Lindsay, a graduate of the Royal College of Dental Surgeons of Ontario in Toronto, left Canada for Chengdu in 1907. With assistance from physician and missionary Omar L. Kilborn, Lindsay established a dental clinic on Sishengci Street. A history published through China's National Health Commission describes the clinic as marking the beginning of modern dentistry in Chengdu. Sichuan University dates the institutional history of the present hospital to the establishment of the Renji Dental Clinic in 1907. It records the expansion of the clinic into the Renji Dental Hospital in 1912. The hospital describes the 1912 institution as China's first specialized dental hospital. West China Union University, a missionary-founded university established in Chengdu in 1910, subsequently became the principal institutional base for Lindsay's dental work. In 1917, the university established its dental education program. The dental school at West China Union University was the earliest dental education institution in China. Several early faculty members were trained at the University of Toronto Faculty of Dentistry, which credits these dentists with helping introduce a university-based model of dental education to China and with contributing to the development of national dental-education standards. In the late 1920s the medical and dental programs of West China Union University were brought into a combined academic structure.
The triple quadrupole mass spectrometer essentially operates under the same principle as the single quadrupole mass analyzer. Each of the two mass filters (Q1 and Q3) contains four parallel, cylindrical metal rods. Both Q1 and Q3 are controlled by direct current (dc) and radio-frequency (rf) potentials, while the collision cell, q, is only subjected to RF potential. The RF potential associated with the collision cell (q) allows all ions that were selected for to pass through it. In some instruments, the normal quadrupole collision cell has been replaced by hexapole or octopole collision cells which improve efficiency. Unlike traditional MS techniques, MS/MS techniques allow for mass analysis to occur in a sequential manner in different regions of the instruments. The TQMS follows the tandem-in-space arrangement, due to ionization, primary mass selection, collision induced dissociation (CID), mass analysis of fragments produced during CID, and detection occurring in separate segments of the instrument. Sector instruments tend to surpass the TQMS in mass resolution and mass range. However, the triple quadrupole has the advantage of being cheaper, easy to operate and highly efficient. Also, when operated in the selected reaction monitoring mode, the TQMS has superior detection sensitivity as well as quantification. The triple quadrupole allows the study of low-energy low-molecule reactions, which is useful when small molecules are being analyzed.
== Competition == Two additional refrigerated train services were announced in 2013, the Green Express, from Tampa, Florida to Kingsbury, Indiana, operated by CSX and the Tampa Port Authority, and the TransCold Express operated by McKay Transcold and BNSF, connecting the California Central Valley with the midwest.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.